GeneFab Launches New cGMP Facility in Alameda
- 42,000 sq ft purpose-built facility opens in Alameda, CA.
- Seven Grade B cleanroom suites in two segregated wings.
- Available capacity to support new customers with complex cell and gene therapy programs.
ALAMEDA, Calif. — July 31, 2023. GeneFab today announced the opening of its new cGMP manufacturing facility in the San Francisco Bay Area. The facility, purpose-built by biotech operators for biotech clients, has available capacity to support cell and gene therapy innovators with complex manufacturing needs.
Built for innovators
The 42,000 sq ft facility was designed end-to-end around the workflows that matter most to cell and gene therapy programs. Seven Grade B cleanroom suites are organized into two fully segregated wings — supporting parallel programs without cross-contamination risk and giving each client team the flexibility to run their process the way it was developed.
The facility supports the full range of modalities our clients work in: autologous and allogeneic cell therapy, viral vector production (lentivirus, gamma-retrovirus, AAV), and critical starting materials including cell isolation and cell banking.
Beyond the cleanrooms
Adjacent to the manufacturing suites, GeneFab's facility includes extensive process development, analytical development, and QC laboratories. Our on-site analytical capability spans environmental monitoring, stability programs, and the full cell and gene therapy release panel — designed to support clients from IND-enabling through commercial supply.
The Alameda site complements GeneFab's Synthetic Biology Center of Excellence in South San Francisco — co-locating manufacturing and research within a single Bay Area footprint, so the team designing a construct can sit just twenty miles from the team scaling it.
Open for partnerships
GeneFab is actively engaging with cell and gene therapy innovators who need a CDMO partner with available capacity and the experience to handle technical complexity. Programs at any stage — discovery, IND-enabling, or clinical supply — are welcome.